


AMENDED CLAIMS


[received by the International Bureau on 04 July 2005 (04.07.2005);
original claims 1, 2, amended, original claims 8-15, 18-25 amended and renumbered, claims
6, 7, 16, 17 cancelled]

1. A compound of formula (I)



or a pharmaceutically acceptable salt thereof, wherein:

-G₁ is a radical (II)




wherein -R' is an electron pair or a (C₁-C₃)-alkyl radical; with the condition that


(i) when -R' is an electron pair, a is a N=C double bond and the fused ring



is the biradical




thus radical (II) is (IIa'), and




(IIa')

(ii) when $-R'$ is a (C_1-C_3) -alkyl radical, a is a N-C single bond and the fused ring is the triradical



thus radical (II) is (IIa'');




(IIa'')

wherein $-R_1$ to $-R_{12}$ represent radicals, same or different, selected from the group consisting of H, (C_1-C_4) -alkyl, (C_1-C_4) -alkoxy, (C_1-C_4) -alkylamino, phenyl, F, Cl, Br, amino, hydroxy, and nitro;

and wherein $-B-$ is a biradical selected from the group consisting of $-C(=O)NH-$,

$-\text{NR}_{13}-$, $-\text{O}-$, $-(\text{CH}_2)_n\text{NH}-$, $-(\text{CH}_2)_n\text{O}-$, and $-\text{CO}[\text{NHCHR}''\text{CO}]_m\text{O}-$; wherein $-\text{R}_{13}$ is selected from the group consisting of H, $(\text{C}_1\text{-C}_4)\text{-alkyl}$, $(\text{C}_1\text{-C}_4)\text{-alkoxy}$ and $(\text{C}_1\text{-C}_4)\text{-alkylamino}$; $-\text{R}''$ are side chains radicals, same or different, corresponding to natural aminoacids; n is an integer from 1 to 3 and m is an integer from 1 to 3;


$-\text{L}-$ is a single covalent bond or a covalent linking biradical selected from the following ones;



wherein $-\text{R}'''$ and $-\text{R}''''$ are radicals, same or different, selected from the group consisting of H and $(\text{C}_1\text{-C}_3)\text{-alkyl}$; r is an integer from 1 to 3; s is an integer from 1 to 3; t is an integer from 1 to 3; and

$-\text{G}_2$ is a radical selected from a radical of formula (II), the N-radical of 1,8-naphthalimide, the C4-radical of 2-phenylquinoline, and the C9-radical of acridine.


2. The compound according to claim 1, wherein (II) is the radical (IIa').




3. The compound according to claim 2, wherein $-\text{B}-$ is selected from the group consisting of $-\text{CONH}-$ and $-\text{NR}_{13}-$.

4. The compound according to claim 2, wherein $-\text{B}-$ is $-\text{CO}[\text{NHCHR}''\text{CO}]_m\text{O}-$.

5. The compound according to claim 4, wherein $m = 2$, the leftward $-R''$ is a glycine side chain, and the rightward $-R''$ is an arginine side chain.
6. The compound according to any of the claims 2-5 wherein $-L-$ is a single covalent bond.
7. The compound according to any of the claims 2-5, wherein $-L-$ is a covalent linking biradical selected from the following ones.



8. The compound according to claim 7, wherein $-L-$ is the biradical $-(CH_2)_rNR'''(CH_2)_s-$, $-R'''$ is methyl, and both r and s are 3.
9. The compound according to claim 7, wherein $-L-$ is the covalent linking biradical $-(CH_2)_rNR'''(CH_2)_sNR'''(CH_2)_t-$, both $-R'''$ and $-R'''$ are methyl; both r and t are 2, and s is 2 or 3.
10. The compound according to claim 1, wherein (II) is the radical (IIa").



11. The compound according to claim 10, wherein $-B-$ is selected from the group consisting of $-CONH-$ and $-NR_{13}-$.
12. The compound according to claim 10, wherein $-B-$ is $-CO[NHCHR''CO]_mO-$.

13. The compound according to claim 12, wherein $\underline{m} = 2$, the leftward $-R''$ is a glycine side chain, and the rightward $-R''$ is the arginine side chain.

14. The compound according to any of the claims 10-13, wherein $-R'$ is methyl.

15. The compound according to claim 14, wherein $-L-$ is a single covalent bond.

16. The compound according to claim 14, wherein $-L-$ is a biradical selected from the following ones.



17. The compound according to claim 16, wherein $-L-$ is the biradical $-(CH_2)_rNR'''(CH_2)_s-$, R''' is methyl, and both r and s are 3.

18. The compound according to claim 16, wherein $-L-$ is the biradical $-(CH_2)_rNR'''(CH_2)_sNR''''(CH_2)_t-$, both $-R'''$ and $-R''''$ are methyl; both r and t are 2, and s is an integer from 2 to 3.

19. The compound according to claim 1, which is selected from the group consisting of:

N-[3-[[3-[(9-acridinecarbonyl)amino]propyl]methylamino]propyl]-10H-indolo[3,2-b]quinoline-11-carboxamide (Ia);

N,N'-(4-methyl-4-azaheptamethylene)-di-(10H-indolo[3,2-b]quinoline-11,11'-carboxamide) (Ib);

N-[3-[3-[[2-(1,3-dioxo-(2,3-dihydro)-1H-benzo[de]isoquinoliny]propyl]methylamino]propyl]-10H-indolo[3,2-b]quinoline-11-carboxamide (Ic);

N-[3-[[3-[(2-phenyl-4-quinolinecarbonyl)amino]propyl]methylamino]propyl]-10H-indolo[3,2-b]quinoline-11-carboxamide (Id);

N,N'-(3,7-dimethyl-3,7-diazanonamethylene)-di-(10H-indolo[3,2-b]quinoline-11,11'-carboxamide) (Ie);

N-[(9-acridinecarbonyl)-3,7,10-triaza-3,7-dimethyldecyl]-10H-indolo[3,2-b]quinoline-11-carboxamide (If);

N,N'-(3,6-dimethyl-3,6-diazaoctamethylene)-di-(10H-indolo[3,2-b]quinoline-11-11'-carboxamide (Ig);

N-[(9-acridinecarbonyl)-3,6-dimethyl-3,6-diazaoctamethylene]-10H-indolo[3,2-b]quinoline-11-carboxamide (Ih);

N-[[1,3-dioxo-(2,3-dihydro)-1H-benzo[de]isoquinolyl]-3,6-dimethyl-3,6-diazaoctamethylene]-10H-indolo[3,2-b]quinoline-11-carboxamide (Ii);

N-[[1,3-dioxo-(2,3-dihydro)-1H-benzo[de]isoquinolyl]-3,7,10-triaza-3,7-dimethyldecyl]-10H-indolo[3,2-b]quinoline-11-carboxamide (Ij);

N,N'-(4-methyl-4-azaheptamethylene)-di-(5-methyl-5H-indolo[3,2-b]quinoline-11,11'-carboxamide) (Im);

N,N'-(4-methyl-4-azaheptamethylen)-di-(5-methyl-5H-indolo[3,2-b]quinoline-11,11'-amine (Iq);

N,N'-(3,7-dimethyl-3,7-diazanonamethylene)-di-(5-methyl-5H-indolo[3,2-b]quinoline-11,11'-carboxamide) (Iy);

N,N'-(3,6-dimethyl-3,6-diazaoctamethylene)-di-(5-methyl-5H-indolo[3,2-b]quinoline-11,11'-carboxamide) (Iz);

(3,7-diazanonamethylene)-di-(10H-indolo[3,2-b]quinoline-11,11'-carboxamide (Iaa);

N,N'-(3,7-dimethyl-3,7-diazanonamethylene)-di-(5-methyl-5H-indolo[3,2-b]quinoline-11,11'-amine (Iab); and

N,N'-(3,6-dimethyl-3,6-diazaoctamethylene)-di-(5-methyl-5H-indolo[3,2-b]quinoline-11,11'-amine (Iac).

20. Use of the compound as defined in any of the claims 1 to 19, for the preparation of a medicament for the treatment of cancer.

21. A pharmaceutical composition comprising a therapeutically effective amount of the compound as defined in any of the claims 1 to 19, together with appropriate amounts of pharmaceutical excipients or carriers.